Mauro Schechter

Instituição:

Universidade Federal do Rio de Janeiro

Centro:

Centro de Ciências da Saúde

Unidade:

Faculdade de Medicina

Departamento:

Departamento de Medicina Preventiva/FM

ORCID:

não disponível no Lattes


Formação:

  • Rockefeller University

    | Pós-Doutorado | 1986 - 1988

  • University of London

    Clinical Tropical Medicine | Doutorado | 1981 - 1985

  • University of London

    Clinical Tropical Medicine | Mestrado | 1980 - 1981

  • Universidade Federal do Rio de Janeiro

    Doenças Infecciosas e Parasitárias | Especialização | 1978 - 1979

  • Universidade Federal do Rio de Janeiro

    Medicina | Graduação | 1971 - 1977
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:

(71.09% artigos com DOI)

Titulo DOI Ano
Could well-established, widely available, and simple laboratory techniques explain a laboratory origin of SARS-CoV-2? 10.1016/j.bjid.2023.102808 2023
Mpox in people with advanced HIV infection: a global case series 10.1016/s0140-6736(23)00273-8 2023
Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil 10.1186/s12879-023-08288-8 2023
Effects of Carbon Nanomaterials and Aloe vera on Melanomas-Where Are We? Recent Updates 10.3390/pharmaceutics14102004 2022
Pre-Exposure Prophylaxis Failure With a Multiple Drug-Resistant HIV-1 Clade C Virus in Brazil 10.1097/qai.0000000000002826 2022
Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk 10.1093/cid/ciac098 2022
Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort 10.1097/QAD.0000000000002988 2021
Is France Once Again Looking for a Scapegoat? 10.20411/pai.v6i2.490 2021
Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors 10.1371/journal.pone.0222183 2019
Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project 10.1089/aid.2018.0297 2019
Prioritization of antiretroviral therapy in patients with high CD4 counts, and retention in care: lessons from the START and Temprano trials 10.1002/jia2.25077 2018
Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial 10.1016/S2352-3018(18)30003-1 2018
Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities 10.1093/cid/ciy008 2018
Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission 10.1016/S0140-6736(18)31070-5 2018
Reply to Kojima and Klausner 10.1093/cid/ciy345 2018
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine 10.1093/cid/ciy083 2018
Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaoundé, Cameroon 10.3851/IMP3165 2017
International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status 10.1097/olq.0000000000000601 2017
Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial 10.1002/jbmr.3183 2017
Recovery of Bone Mineral Density Following Discontinuation of Tenofovir-Based HIV Pre-Exposure Prophylaxis 10.1097/qai.0000000000001475 2017
Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial 10.1093/ofid/ofx262 2017
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension 10.1093/cid/ciw022 2016
The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study 10.1007/s10461-016-1415-9 2016
Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets 10.1007/s11904-016-0325-9 2016
Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study 10.1016/S2352-3018(16)30153-9 2016
Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial 10.1111/hiv.12231 2015
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial: DXA Results from iPrEx 10.1093/cid/civ324 2015
Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring 10.1093/infdis/jiv239 2015
The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels 10.1097/QAD.0000000000000675 2015
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption 10.1038/ncomms9495 2015
Modeling the Slow CD4+ T Cell Decline in HIV-Infected Individuals 10.1371/journal.pcbi.1004665 2015
Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression 10.1097/QAD.0000000000000155 2014
Continuous Increase of Cardiovascular Diseases, Diabetes, and Non-HIV Related Cancers as Causes of Death in HIV-Infected Individuals in Brazil: An Analysis of Nationwide Data 10.1371/journal.pone.0094636 2014
HIV Provider-Patient Communication Regarding Cardiovascular Risk: Results from the 2010 AIDS Treatment for Life International Survey 10.1177/2325957414530473 2014
HIV-1 DNA predicts disease progression and post-treatment virological control 10.7554/eLife.03821 2014
Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection 10.7448/IAS.17.4.19480 2014
Streamlining HIV Testing for HIV Preexposure Prophylaxis 10.1128/JCM.01540-14 2014
Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study 10.1097/QAI.0000000000000351 2014
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study 10.1016/S1473-3099(14)70847-3 2014
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis 10.1097/qad.0000000000000156 2014
Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex With Men in a Preexposure Prophylaxis Trial 10.1093/cid/ciu450 2014
Mortality in Well Controlled HIV in the Continuous Antiretroviral Therapy Arms of the SMART and ESPRIT Trials Compared to the General Population 10.1097/QAD.0b013e32835cae9c 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials 10.1016/S1473-3099(13)70093-8 2013
Short-Course Antiretroviral Therapy in Primary HIV Infection 10.1056/nejmoa1110039 2013
Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection 10.1097/qad.0b013e32835b8cf5 2013
Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study 10.1371/journal.pone.0056249 2013
Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters 10.1186/1742-4690-10-8 2013
Rating evidence in treatment guidelines 10.1097/QAD.0b013e328360d546 2013
Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy 10.1371/journal.pone.0078287 2013
Duration of Anti-Tuberculosis Therapy and Timing of Antiretroviral Therapy Initiation: Association with Mortality in HIV-Related Tuberculosis 10.1371/journal.pone.0074057 2013
Antiviral efficacy of entecavir in nucleos(t)ide-naïve patients of Black/African descent with chronic hepatitis B 10.1111/jvh.12144 2013
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings 10.1186/1471-2334-12-147 2012
Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men 10.1126/scitranslmed.3004006 2012
Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection 10.1371/journal.pone.0043754 2012
The Development of PROQOL-HIV 10.1097/QAI.0b013e318245cafe 2012
HIV-Related Stigma, Isolation, Discrimination, and Serostatus Disclosure: A Global Survey of 2035 HIV-Infected Adults 10.1177/1545109712436723 2012
Late Diagnosis of HIV Infection in Brazil Despite over 15 Years of Free and Universal Access to Treatment 10.1089/aid.2012.0077 2012
Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study) 10.1093/infdis/jis342 2012
Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection 10.1097/qad.0b013e328351e721 2012
Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America 10.1186/1758-2652-15-5 2012
HIV Treatment Adherence, Patient Health Literacy, and Health Care Provider-Patient Communication: Results from the 2010 AIDS Treatment for Life International Survey 10.1177/1545109712437244 2012
Estimating the Extent of Underreporting of Mortality Among HIV-Infected Individuals in Rio de Janeiro, Brazil 10.1089/aid.2010.0089 2011
World Health Organization Guidelines Group. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. 2011
The DART Trial: The ?Doctor?s Dilemma? revisited 10.1093/jac/dkr020 2011
Cancer in HIV-Infected Persons From the Caribbean, Central and South America 10.1097/QAI.0b013e31820bb1c3 2011
Tuberculosis in HIV programmes in lower-income countries: practices and risk factors 10.5588/ijtld.10.0249 2011
Prevalence and risk factors associated with syphilis in a cohort of HIV positive individuals in Brazil 10.1080/09540121.2011.597706 2011
Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis 10.1371/journal.pone.0022003 2011
A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204) 10.1371/journal.pone.0021225 2011
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis 10.1056/nejmoa1013607 2011
Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants 10.1186/1742-4690-8-54 2011
Egocentric network data provide additional information for characterizing an individualʼs HIV risk profile 10.1097/qad.0b013e328333eb81 2010
Longâ¿¿Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatmentâ¿¿Experienced Patients with Drugâ¿¿Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials 10.1086/650002 2010
Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings 10.1097/qai.0b013e3181c22d19 2010
Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities 10.1097/coh.0b013e328333ad61 2010
Prioritising prevention strategies for patients in antiretroviral treatment programmes in resource-limited settings 10.1080/09540120903349102 2010
Rates and Reasons for Early Change of First HAART in HIV-1-Infected Patients in 7 Sites throughout the Caribbean and Latin America 10.1371/journal.pone.0010490 2010
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs 10.1016/S0140-6736(10)60829-X 2010
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials 10.1016/j.vaccine.2009.10.145 2010
Evaluation of Three Sampling Methods to Monitor Outcomes of Antiretroviral Treatment Programmes in Low- and Middle-Income Countries 10.1371/journal.pone.0013899 2010
Monitoring Antiretroviral Therapy in Resource-Limited Settings: Balancing Clinical Care, Technology, and Human Resources 10.1007/s11904-010-0046-4 2010
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men 10.1056/nejmoa1011205 2010
Modelling the evolution and spread of HIV immune escape mutants 2010
Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials 10.1310/hct1104-205 2010
Mortality after failure of antiretroviral therapy in sub-Saharan Africa 10.1111/j.1365-3156.2009.02445.x 2010
Association Between Male Circumcision and Prevalent HIV Infections in Rio de Janeiro, Brazil 10.1097/qai.0b013e3181958591 2009
Interruption of antiretroviral therapy is associated with increased plasma cystatin C. 2009
Barriers to Recruit Female Commercial Sex Workers for HIV Vaccine Trials: The Rio de Janeiro Experience 10.1097/qai.0b013e31818d5e3f 2009
Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy 10.1111/j.1365-3156.2009.02338.x 2009
Switching to second-line therapy antiretroviral therapy in resource-limited settings:omparison of programmes with and without access to viral load monitoring. 2009
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials 10.1097/qad.0b013e3283316a5e 2009
Risk-based assessment does not distinguish between recent and chronic HIV-1 infection in Rio de Janeiro, Brazil 10.1590/s1413-86702009000400006 2009
Monotherapy with Lopinavir/Ritonavir as Maintenance After HIV-1 Viral Suppression: Results of a 96-Week Randomized, Controlled, Open-Label, Pilot Trial (KalMo Study) 10.1310/hct1006-368 2009
Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial 2009
HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. 2009
Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the Caribbean 10.1097/QAI.0b013e3181a44f0a 2009
Temporal Changes in Causes of Death Among HIV-Infected Patients in the HAART Era in Rio de Janeiro, Brazil 10.1097/QAI.0b013e3181a4ecf5 2009
Gender and the Use of Antiretroviral Treatment in Resource-Constrained Settings: Findings from a Multicenter Collaboration 10.1089/jwh.2007.0353 2008
Overcoming resistance to existing therapies in HIV-infected patients: The role of new antiretroviral drugs 10.1002/jmv.21034 2008
Antiretroviral therapy in resource-limited settings, 1996 to 2006: Patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. 2008
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries 2008
Potential for New Antiretrovirals to Address Unmet Needs in the Management of HIV-1 Infection 10.1089/apc.2007.0136 2008
The Use of Supplementary Techniques to Increase Recall of Sex Partners in a Network-Based Research Study in Rio de Janeiro, Brazil 10.1097/olq.0b013e31816b323d 2008
Validation of a Hierarchical Deterministic Record-Linkage Algorithm Using Data From 2 Different Cohorts of Human Immunodeficiency Virus-Infected Persons and Mortality Databases in Brazil 10.1093/aje/kwn249 2008
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies 10.1097/qad.0b013e3283121ca9 2008
Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy. HIV Med. 2008
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study 2008
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up 2008
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized tria 2008
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen 10.1097/QAD.0b013e328311d16f 2008
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept tria 2008
HIV-1 vaccine-induced immunity in the test-of-concept. Step Study: a case?cohort analysis. 2008
Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil 10.1371/journal.pone.0001531 2008
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection 10.1056/nejmoa0708978 2008
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection 10.1056/nejmoa0708975 2008
Treatment at scale in Brazil: a physician??s perspective 10.1097/01.aids.0000279704.16804.ae 2007
Tuberculosis after Initiation of Antiretroviral Therapy in Low-Incone and High-Income Countries 2007
Discordant Responses to Potent Antiretroviral Treatment in Previously Naive HIV-1-Infected Adults Initiating Treatment in Resource-Constrained Countries 10.1097/qai.0b013e318042e1c3 2007
Effectiveness of highly active antiretroviral therapy using non-brand name drugs in Brazil 10.1590/s0100-879x2007000400014 2007
Monotherapy with lopinavir/ritonavir 10.1517/13543784.16.5.735 2007
Lessons From a Multisite International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120 10.1097/QAI.0b013e318149297d 2007
Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme 10.1093/ije/dym073 2007
Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy 10.1016/j.jinf.2005.06.002 2006
Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts 10.1164/rccm.200512-1953oc 2006
Limited Penetration of Lopinavir and Ritonavir in the Genital Tract of Men Infected with HIV-1 in Brazil 10.1097/01.ftd.0000180225.27008.8c 2006
Cross-Clade Reactivity of HIV-1-Specific T-cell Responses in HIV-1-Infected Individuals From Botswana and Cameroon 10.1097/01.qai.0000223017.01568.e7 2006
HIV/AIDS research in Brazil: the missing piece? 10.2217/17460794.1.4.409 2006
Discordant immunologic and virologic responses to antiretroviral therapy 10.1093/jac/dkl263 2006
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society?USA Panel 2006
Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. 2006
Viral Load and CD4 Count Dynamics After HIV-1 Seroconversion in Homosexual and Bisexual Men in Rio de Janeiro, Brazil 10.1097/01.qai.0000243117.21788.90 2006
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial 10.1016/s0140-6736(06)69074-0 2006
Incident HIV Infection in a High-Risk, Homosexual, Male Cohort in Rio de Janeiro, Brazil 10.1097/01.pas.0000213299.11649.107 2006
Mortality of HIV-infected patients in low-income countries - Authors? response 10.1016/S0140-6736(06)69887-5 2006
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries 10.1016/s0140-6736(06)68337-2 2006
Predictors of Virologic Failure in HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy in Porto Alegre, Brazil 10.1097/01.qai.0000182627.28595.01 2005
Cross-Reactivity of Anti-HIV-1 T-Cell Immune Responses Among the Major HIV-1 Clades in HIV-positive Individuals from Four Continents. 2005
Antiretroviral therapy in resource-poor settings: scaling up inequalities? 10.1093/ije/dyi110 2005
Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts 10.1093/ije/dyi164 2005
High Prevalence of sexually transmitted diseases in young women seeking HIV testing in Rio de Janeiro, Brazil 2004
Behavioral Impact, Acceptability, and HIV Incidence Among Homosexual Men With Access to Postexposure Chemoprophylaxis for HIV 10.1097/00126334-200404150-00010 2004
Effectiveness of Antiretroviral Therapy Among Patients Who Attend Public HIV Clinics in Rio de Janeiro, Brazil 10.1097/00126334-200408010-00011 2004
Therapy of early HIV infection: How far back should the pendulum swing? 2004
Identification of a High-Risk Heterosexual Cohort for HIV Vaccine Efficacy Trials in Rio de Janeiro, Brazil, Using a Sensitive/Less-Sensitive Assay: An Update 10.1097/00126334-200407010-00019 2004
Triple Nucleoside Treatment with Abacavir Plus the Lamivudine/Zidovudine Combination Tablet (COM) Compared to Indinavir/COM in Antiretroviral Therapy-naïve Adults: Results of a 48-Week Open-label, Equivalence Trial 2004
Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine 2004
Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1 10.1371/journal.pmed.0010019 2004
Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel 10.1001/jama.292.2.251 2004
Adherence to Antiretroviral Therapy and Persistence of HIV RNA in Semen 10.1097/00126334-200304010-00014 2003
Scaling up Antiretroviral Therapy in Resource-Limited Settings: Guidelines for a public health approach 2003
Reduced Risk of Tuberculosis among Brazilian Patients with Advanced Human Immunodeficiency Virus Infection Treated with Highly Active Antiretroviral Therapy 10.1086/338641 2002
Scaling up Antiretroviral Therapy in Resource-Limited Settings: Guidelines for a public health approach. 2002
HIV vaccine evaluation center in Rio de Janeiro, Brazil 10.1016/S0264-410X(02)00065-8 2002
Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel 10.1001/jama.288.2.222 2002
A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis 10.1056/nejmoa011759 2002
A Safety Study of Oral Valganciclovir Maintenance Treatment of Cytomegalovirus Retinitis 2002
Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil 2001
An international, randomized trial of Rifampin and Pyrazinamide versus Isoniazid for prevention of tuberculosis in HIV-infected persons 2000
Antiretroviral Therapy for HIV Infection: Updated Recomendations of the International AIDS Society-USA Panel. 2000
HIV-Disease Progression and V3 serotypes in Brazil: Is B Different from B-Br? 10.1089/08892220050058362 2000
Effect of Antiretroviral Therapy on HIV Shedding in Semen 10.7326/0003-4819-133-4-200008150-00012 2000
Acute Retrovirus Syndrome among Prospectively-Identified Homosexual Males with Incident in Brazil 2000
Brief Report: Identification of a High-Risk Heterosexual Population for HIV Prevention Trials in Rio de Janeiro, Brazil 10.1097/00126334-200006010-00013 2000
Willingness to participate in HIV Vaccine trials among men who have sex with men in Rio de Janeiro 2000
Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected Persons: An International Randomized Trial 10.1001/jama.283.11.1445 2000
Protease Inhibitors as Initial Therapy for Individuals with an Intermediate Risk of HIV Disease Progression: Is More Necessarily Better? 1999
Dual and Recombinant Infections: An Integral Part of the HIV Epidemic in Brazil. 1999
Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil 1999
Horizontal And Vertical Transmission Of Hiv-1 Dual Infections Caused By Viruses Fo Subtypes B And C. 1998
Molecular and Epidemiologic Evidence for the Discontinuous Introduction of Subtypes B and F Into Rio de Janeiro, Brazil 10.1097/00042560-199811010-00017 1998
Coinfection with HTLV-I and HIV: Increase in HTLV-I- related outcomes but not accelerated HIV disease progression? 1998
Comparison of the Prevalence of Antibodies to Human herpesvirus-8 (Kaposi's Sarcoma- Associated Herpesvirus) in Brazil and in the United States 1998
Gender and Survival After AIDS in Rio de Janeiro, Brazil 10.1097/00042560-199812010-00012 1998
Human T Cell Lymphotropic Virus Type I Does Not Increase Human Immunodeficiency Virus Viral Load In Vivo 10.1093/infdis/175.2.438 1997
The future of tropical medicine: a Brazilian perspective 1997
Human T Cell Lymphotropic Virus Type II and Human Immunodeficiency Virus Type 1 Disease Progression 10.1086/514035 1997
Coinfection with Human T Lymphotropic Virus Type I and Human Immunodeficiency Virus (letter). 1997
Detection of genetically diverse Human Immunodeficiency Virus Type I group M and O isolates by PCR 1997
Myelopathy Among Brazilians Coinfected with Human T-cell Lymphotropic Virus Type I and HIV 10.1212/wnl.48.1.13 1997
HIV Viral Load and CD4+ Lymphocyte Counts in Subjects Coinfected With HTLV-I and HIV-1 10.1097/00042560-199708010-00010 1997
Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis. 1996
A nationwide effort to systematically monitor HIV-1 diversity in Brazil: preliminary results 1996
Human T Lymphotropic Virus Type I and II Infections in Healthy Blood Donors from Rio de Janeiro, Brazil 10.1111/j.1423-0410.1996.tb00999.x 1996
Antibiotic regimen as an independent risk factor for disseminated fungal infections in neutropenic patients in Brazil 10.1016/0035-9203(95)90677-0 1995
Sequence and Phylogenetic Analysis of Glycoprotein 120 of an HIV Type 1 Variant (GWGR) Prevalent in Brazil 10.1089/aid.1995.11.1143 1995
HIV-1 patients harbor viruses belonging to different subtypes: implication for the evolution of the pandemic 1995
CD4+ blood lymphocytes are rapidly killed in vitro by contact with autologous immunodeficiency virus-infected cells 1995
V3 peptide binding pattern and HIV-1 transmission route in Rio de Janeiro 1995
Predicting CD4 counts in HIV-infected Brazilian individuals: a model based on the World Health Organization staging system 1994
Urinary tract infection in men with AIDS. 10.1136/sti.70.1.30 1994
P24 antigenemia in HIV-1 infected brazilian individuals correlates with other markers of disease progression 1994
Co-infection with Human T-Cell Lymphotropic Virus Type I and HIV in Brazil: Impact on CD4 Lymphocyte counts and Clinical Stage 1994
Prevalence of antibodies to Hepatitis C virus in populations at low and high risk for Sexually transmitted diseases in Rio de Janeiro, Brasil 1993
Survival of HIV-infected Brazilian individuals: a model based on the World Health Organization staging system 1993
PPD reactivity and risk of development of tuberculosis in HIV infected brazilian patients. 1993
Breast-feeding and vertical transmission of HIV-1 in Rio de Janeiro, Brazil. 1993
AIDS case definitions in developing countries 1993
HTLV I associated neurological manifestations in 4 generations of a Brazilian family 1993
Pulmonary tuberculosis in sputum-negative Brazilian AIDS patients 10.1378/chest.101.4.1184 1992
Complicacoes neurologicas na sindrome de imunodeficiencia adquirida 1991
Papovavirus associated esofageal ulceration in a patient with AIDS 1991
Bacteriuria in patients with CDC group IV manifestations : A prospective study. 1991
Leprosy as a cause of false positive results in serological assays for the detection of antibodies to HIV-1 1991
Variations induced by different methodologies in Trypanosoma cruzi surface antigen profiles 10.1016/0166-6851(88)90117-x 1988
Evaluation of a monoclonal antibody affinity purified antigen for zymodeme specific serological diagnosis of Trypanosoma cruzi infection 1987
Prevalence of antibodies to a 72 Kilodalton glycoprotein (GP72) in patients with Chagas'disease and further evidence for zymodeme associated expression of GP72 carbohydrate epitopes 1986
Trypanosoma cruzi: Characterization and isolation of a 57/51,000 mw surface glycoprotein (GP57/51) expressed by epimastigotes and bloodstream trypomastigotesEpimastigotes End Bloodstream Trypomastigotes. 1986
Further evaluation of lectin affinity purified glycoprotein (GP90) in the enzyme linked immunosorbent assay (ELISA) for diagnosis of Trypanosoma cruzi infection 10.1016/0035-9203(85)90176-2 1985
Investigations on the expression of a 72,000 molecular weight surface glycoprotein (GP72) in T. cruzi zymodemes and detection of anti-GP72 antibodies in Chagasic patients 1985
Zymodeme and species specificities of monoclonal antibodies raised against Trypanosoma cruzi 10.1016/0035-9203(84)90276-1 1984
PURIFIED TRYPANOSOMA CRUZI SPECIFIC GLYCOPROTEIN FOR DISCRIMINATIVE SEROLOGICAL DIAGNOSIS OF SOUTH AMERICAN TRYPANOSOMIASIS (CHAGAS' DISEASE) 10.1016/S0140-6736(83)90453-1 1983
Eventos:

(0.00% eventos com DOI)

Titulo DOI Ano
iPrEx Study Team. Results of the iPrEx open-label extension (iPrEx OLE) in men and transgender women who have sex with men: PrEP uptake, sexual practices, and HIV incidence 2014
Patterns and Correlates of PrEP Drug Detection among MSM and Transgender Women in the Global iPrEx Study 2014
iPrEx Study Team. Drug detection during open-label extension of the iPrEx trial indicates sustained and appropriate interest in PrEP among men who have sex with men 2014
Changes in Renal Function during Use of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis: iPrEx 2013
Drug detection during open-label extension of the iPrEx trial indicates sustained and appropriate interest in PrEP among men who have sex with men. 2013
Efficacy and Safety of Raltegravir Among Latin American Patients in STARTMRK. 2013
Mortality in Patients with Well-controlled HIV and High CD4 Counts in the cART Arms of the SMART and ESPRIT Randomized Clinical Trials Compared to the General Population 2012
Interleukin-6 and D-dimer at HIV Seroconversion as Predictors of HIV Disease Progression 2012
Antiviral Efficacy of Entecavir in Black/African American and Hispanic Patients with Chronic Hepatitis B who are Nucleos(t)ide-Naïve 2012
Prioritizing PrEP among MSM for Greatest Efficacy: An Analysis of the iPrEx Data 2012
Oral TDF and Its Impact in HSV-2 Acquisition and Clinical Expression 2011
Local risk indicators key for targeting PrEP. 2011
Completed observation of the randomized placebo-controlled phase of iPrEx: daily oral FTC/TDF pre-exposure HIV prophylaxis among men and trans women who have sex with men 2011
Hepatic Safety and Tolerability of Etravirine: Pooled 96-week Analysis of DUET-1 and DUET-2 2010
A Comparison of HIV Viral Rebound following ART Cessation in Primary and Chronic HIV Infection 2010
Prediction of CD4 cell count slope in patients with virological failure to first-line of antiretroviral combinations in resource-limited settings 2009
Using the yearly proportion of patients with undetectable viral load - a WHO indicator of HAART effectiveness - in a middle-income country 2009
Differences in heath-related quality of life (HRQL) measured by the PROQOL-HIV, a new specific instrument developed across cultures 2009
HIV/AIDS clinical mentoring results in increased access to trained health workers and improved care 2009
Correcting mortality for loss to follow up: a graphical approach applied to ART programmes in resource-limited settings 2009
Psychometric validation of PROQOL-HIV a contemporaneous and cross-cultural health-related quality-of-life (HRQL) questionnaire specificific 2009
Comparison of WHO vs CDC staging system in predicting mortality at 2 years of HAART HIV-1 infected adults initiating treatment in resource-constrained countries 2009
Prioritising prevention strategies for patients in antiretroviral treatment programmes in resource-limited settings 2009
48-Week Results from BENCHMRK-2, a Phase III Study of Raltegravir in Patients Failing ART with Triple-class Resistant HIV 2008
Mortality of HIV-1-infected Patients Starting ART in Sub-Saharan Africa: The IeDEA Prognostic Model 2008
Effect of Early Immunovirologic Discordant Responses on Mortality in Naïve HIV-1-infected Adults Initiating Treatment in Resource-constrained Countries 2008
Mortality during the first year of potent antiretroviral therapy in HIV-1-Infected patients from 5 treatment centers in the Caribbean and Latin America 2008
Reasons for change of first potent antiretroviral therapy in HIV-1-Infected patients in 5 sites throughout the Caribbean and Latin America 2008
Underreporting deaths among HIV-Infected/AIDS patients in Rio de Janeiro, Brazil 2008
Incidence and severity of nervous system and psychiatric events are similar with etravirine (TMC125, ETR) versus placebo: pooled 48-week date from the phase III DUET studies 2008
Results of BENCHMRK-2, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus 2007
Significant increases in cardiovascular diseases and diabetes as causes of death in HIV-infected individuals in the HAART era in Brazil: a population based analysis 2007
Risk Factors for Recent HIV-1 Infection at an HIV Testing Site in Rio de Janeiro, Brazil: A Case-Control Study 2007
96-week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/mL on HAART - the KalMo study 2007
Identification of Risk Factors for Recent HIV-1 Infection in a HIV Testing Site in Rio de Janeiro, Brazil 2007
Barriers to recruit female commercial sex workers for HIV vaccine trials: The Rio de Janeiro Experience 2007
TMC125 Safety and Tolerability in Treatment-Experienced Hepatitis B or C Co-infected Patients in DUET-1 and DUET-2 2007
When Are Adults in Resource-constrained Settings Most Likely to Experience an HIV-associated Illness following HAART Initiation and What Is It Related To? 2006
Discordant Immunologic and Virologic Responses to ART among Previously Naive Adults Initiating HAART in Resource-constrained Settings 2006
Censoring issues in observational HIV treatment cohorts: describing different approaches to censoring and their effects on estimates of mortality and losses to follow-up in a multinational cohort collaboration from resource-constrained settings 2006
Life expectancy of HIV-infected men and women initiating HAART in resource-constrained settings: insights from the ART-LINC collaboration 2006
Clinical mentoring: tapping into the vast, mostly neglected, western resources to make a fast, sustainable, and effective contribution to putting AIDS patients on ART in developing countries 2006
Relationship of egocentric network characteristics and HIV transmission among MSM in Rio de Janeiro, Brazil 2006
Building and retaining a group of potential volunteers for HIV vaccine trials in Rio de Janeiro, Brazil 2006
48-week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/mL on HAART - the KalMo study 2006
Response to Highly Active Retroviral Therapy in Low- and High-income Countries: Analysis of Clinical Databases from 4 Continents. 2005
Predictors of Virological Failure at 6 Months of Therapy in HIV-1-infected Patients Starting HAART in Porto Alegre, Brazil 2005
Generic drugs, health delivery mode and effectiveness of HAART in Brazil. 2005
Prognostic value of baseline total lumphocyte count (TLC) vs, absolute CD4 count in predicting survival among patients initiating HAART in low-income countries 2005
Leveraging Western medical expertises to rapidy build healthcare systems for HIV/AIDS in developing countries. 2005
The effectiveness of clinical mentoring as a method to improvee HIV/AIDS clinical skills of healthcare professionais in Cambodia 2005
How do different types of treatment regimens affect short-term response to Highly Active Antiretroviral Treatment (HAART) among adults initiating treatment in low-income countries? 2005
Gender, access and response to potent antiretroviral in low-income countries: ART-LINC Collaboration 2005
Short-term incidence and risk factors for being lost to treatment in 16 antiretroviral treatment cohorts in low income countries 2005
Course of human immunodeficiency virus type 1 infection after seroconversion in a cohort of men who have sex with men (MSM) in Rio de Janeiro, Brazil 2005
Epidemiology of Human Pre-Existing Anti-Adenovirus type-6 and (AD6) and type-5 (AD5) Neutralizing Antibodies (NA) in Areas Representative of Potential HIV Vaccine Trials Sites 2005
HIVNET 026: A Multi-Site International Trial of na HIV-1 Canarypox Vaccine (ALVAC-HIVVCP 1452) With or Without Boosting With MN RGP 120 2005
Study on the feasibility of antiretroviral therapy with a single agent-Lopinavir/r- in patients treated with HAART and with viral load below 80 copies/ml-KalMo. 2005
HIV post-sexual exposure prophylaxis 2004
Factors associated with antiretroviral adherence in public clinics in Rio de Janeiro, Brazil 2004
Morisky questions as a tool to evaluate adherence to antiretroviral therapy in public primary care clinics in Rio de Janeiro, Brazil 2004
Involving community members in HIV vaccine research programs 2004
Poor penetration of lopinavir in the genital tract of men receiving HAART in Brazil. 2004
Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy 2004
International epidemiology of human pre-existing anti-adenovirus Type-5 (Ad5) neutralizing antibodies in areas representative of potential HIV vaccine trial sites 2004
Retention of subjects in a multi-site international epidemiology study In preparation of large scale HIV vaccine efficacy trials 2004
Recruitment of a high-risk heterosexual cohort for HIV vaccine efficacy trials in Rio de Janeiro, Brazil: Risk profile and willingness to participate in vaccine trials 2004
Characteristics of ART treatment programmes in low-income countries: the ART-LINC collaboration 2004
Recruitment and retention of a high-risk heterosexual cohort for HIV vaccine efficacy trials in Rio de Janeiro, Brazil: risk profile and willingness to participate in vaccine trials 2004
Lipid Changes in a Randomized Comparative Trial of First-line Antiretroviral Therapy with Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together with Stavudine and Lamivudine (2NN Study). 2003
Risk Factors for Kaposi?s Sarcoma-associated Herpesvirus Infection among Homosexual Men at Hight Risk for HIV Infection in Brazil 2003
Safer Sex After Initiation of Antiretroviral Therapy in a Public HIV Clinic in Brazil 2003
Risk Factors for HIV and STDs among Young Women Seeking HIV Testing in Rio de Janeiro 2003
Large Scale use of Antiretroviral Drugs is not Associated with a High Prevalence of Genotypic Resistance Mutations in Treatment-Naive HIV-1 Infected Individuals in Rio de Janeiro, Brazil. 2003
Is Natural Selection Involved in the Rapid Expansion of GWGR Subtype B Variant in Brazil? 2003
Identification of a High-Risk Heterosexual Cohort for HIV Vaccine Efficacy Trials in Rio de Janeiro, Brazil 2003
HIV and STI Interactions Among Young Women Seeking HIV Testing in Rio de Janeiro. 2003
International Epidemiology Human Pre-existing Anti-Adenovirus Type-5 (Ad5) Neutralizing Antibodies in Areas Representative of Potential HIV Vaccine Trial Sites. 2003
Conduct of a Mmulti-site HIV Vaccine Trial (HIVNET026) in the Caribbean and South America 2003
Feasibility of Multiside International Epidemiologic Studies in Preparation of Large Scale HIV Vaccine Efficacy Trials 2003
Projeto Praça Onze. Recruitment of a High-risk Heterosexual Cohort for HIV Vaccine Efficacy Trials in Rio de Janeiro, Brazil. 2003
Acceptability, Behaioral Impact, and Possible Efficacy of Post-Sexual-Exposure Chemoprophylaxis (PEP) for HIV 2002
Community participation on HIV vaccine research in Brazil 2002
Effectiveness of antiretrovirais in patients who attend HIV clinics in Rio de Janeiro, Brazil 2002
Frequent presence of polymorphisms in the protease and reverse transcriptase genes of viruses obtained from treatment-naive Brazilian patients 2002
HIV-infected marginalized and abused women from Rio de Janeiro, Brazil are heavily coinfected with HPV but have low/moderate prevalence for other sexually transmitted infections 2002
High HPV viral load associated with advanced immunodeficiency and pre-invasive cervical lesions in HIV infected women in Rio de Janeiro 2002
High prevalence of HIV and sexually transmitted infectious among young women seeking HIV testing in Rio de Janeiro 2002
Non-hodgkin lymphoma associated to HIV infection: a case report 2002
Reactivity of anti-HIV T-cell immune responses to different HIV-1 subtypes among HIV+ individuals from Brazil, Thailand and the US 2002
Sexual Activity after initiation of antiretroviral therapy in Brazil 2002
Abacavir/Combivir (ABC/COM) is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-week Open Label Study (CNA3014) 2001
Post-Sexual-Exposure Chemoprophylaxis (PEP) for HIV: A Prospective Cohort Study of Behavioral Impact 2001
Reduced Risk of Tuberculosis (TB) Among Patients with HIV infection Treated with HAART in a Brazilian Cohort 2001
Citomegalovirose no Transplante Renal. Possível Associação com o uso de Micofenolato Mofetil 2001
Dynamics of HIV replication is semen comportament is higher than that in blood compartment 2001
Evidence for Two Different Phylogenetic Distribution patientes of GWGR and GPGR Variants of Subtype B HIV-1 Viruses in Brazil 2001
Infecções por Bactérias Multi-resistentes. Problema Emergente no Transplante Hepático 2001
Behavioral Impact of the Avaliabillity of Post Sexual Exposure Chemoprophylaxis(PEP) for HIV: A prospective Cohort Study 2001
Rebound of Seminal HIV-1 Viral Load Associated with Sexually Transmitted Diseases (STDs) after Virologic Suppression by Antiretroviral Therapy. 2000
Sensitive/Less-Sensitive HIV Testing Strategy to Identify a High-Risk Heterosexual Population in Brazil 2000
Demand for Post-Sexual-Exposure Chemoprophylaxis for the Prevention of HIV Infection in Brazil 2000
Predictors of Seminal Viral Load (SVL) Supression in Subjects Starting Antiretroviral Therapy (ART). 2000
Risk factors for HPV infection in a cohort of HIV-1 infectecd women with a high prevalence of co-infection by oncogenic HPV 2000
Tuberculosis and survival of HIV-infected patients in an area with a high prevalence of M.tuberculosis infection. 2000
Homosexuality and willingness to participate in an HIV vaccine trial. 2000
Acceptability of Post-Sexual-Exposure Chemoprophylaxis for the Prevention of HIV Infection in Brazil 2000
Reduced Risk of Tuberculosis (TB) among Patients with HIV Infection Treated with Highly Active Antiretroviral Therapy (HAART) 2000
Perception of risk and regular partnership among MSM in Rio de Janeiro, Brazil. HPV 2000
Tuberculose (TB) em Receptores de Transplante Renal (RTR) 2000
Seminal HIV-1 Viral Load Is Reduced by Antiretroviral Therapy and Is Correlated with Plasma HIV-1 Viral Load 1999
A High-Incidence Homosexual Male Cohort for Vaccine Trials in Brazil. 1999
V3- Binding Serotypes and HIV Disease Progression in Brazil: Is B Different from B'?. 1999
The Sensitive/Less Sensitive HIV Testing Strategy to Identify a High-Risk Heterosexual Population for HIV Vaccine Trials in Brazil. 1999
Demand for Post- Sexual-Exposure Chemophophylaxis for the Prevention of HIV Infection in Brazil 1999
Seminal HIV-1 Shedding is Increased by the Presence of Genital Warts. 1999
Adherence to Antiretroviral Therapy (ART) is Associated with Seminal Viral Load (SVL) Supression 1999
The absence of a definition of Acute Retroviral Syndrome (ARS) in a Cohot of HIV-Seronegative Homosexual Men in Brazil 1999
Sorotipo da Infecção pelo HIV no Rio de Janeiro 1999
Estudo da Resposta Imune na Coinfecção HTLV-I/HIV 1999
Molecular and epidemiologic evidence for the discontinuous introduction of subtypes B and F into Rio de Janeiro, Brazil 1998
Impact of anti-retroviral therapy on HIV-1 seminal viral load. 1998
Prevalence of markers for sexually transmitted diseases in a male population at high risk for HIV infection 1998
Risk factors for tuberculosis (TB) in a cohort of HIV-infected patients in Rio de Janeiro, Brazil 1998
Unprotected oral sex among men who have sex with men (MSM) 1998
High correlation between plasma and seminal HIV-1 viral load in antiretroviral-naive Brazilian subjects. 1998
Willingness to participate in a vaccine preparatory study in Rio de Janeiro, Brazil 1998
Gender and progression of HIV-associated immunodeficiency. 1998
Sobrevida Após Sida: Estudo Comparativo Entre Sexos. 1997
Incidência de Tuberculose Em Uma Coorte de Pacientes Com Infecção Pelo Vírus da Imunodeficiência Humana 1997
Ausência de Associação Entre O Sistema de Estágios da Oms e Carga Viral do Vírus da Imunodeficiência Humana (Hiv) 1997
Horizontal and Vertical Transmission of HIV-1 Dual Infections Caused by Viruses of Subtypes B and C 1997
HIV viral load and CD4 lymphocyte counts in subjects coinfected with HTLV-1 and HIV-1. 1997
Endocarditis Due to Corynebacterium diphtheriae: Case Report. Fourth International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, 1997
Análise do polimorfismo do gene da protease do HIV- 1 em amostras do Rio de Janeiro 1997
Soroprevalência do Herpes simplexvirus em doadores de sangue e em uma população masculina de alto risco para a infecção pelo HIV. 1997
Hiv-1 Infections In Brazil: Single, Duals And Recombinants 1996
Multicentre Evaluation Of Alternative Methods For Cd4 Lynphocyte Determination 1996
Incidence Of Tuberculosis In A Cohort Of Hiv-1 Infected Women In Rio de Janeiro, Brazil. 1996
High Prevalence Of Stds And Hig-Risk Behavior Among Men Who Have Sex With Men In An Hiv Seroincidence Study In Brazil 1996
Recruitment For An Hiv Seroincidence Study In Brazil: Alternative Approaches And Lesson Learned 1996
Willingness Of Participants In An Hiv Seroincidence Study In Rio de Janeiro, Brazil To Participate In Future Vaccine Trials. 1996
Frequency Of Subtypes Of Hiv-1 In Participants Off A Cohort Study In Rio de Janeiro, Brazil, As Suggested By Endonuclease Digestion Patterns Of The Protease Gene. 1996
Differences In The Prevalence Of Hiv-1 Subtypes In Male And Female Participants Of A Cohort Study In Rio de Janeiro, Brazil. 1996
Natural History Of Hiv-1 Infection In Women In Rio de Janeiro, Brazil 1996
Impact Of Antiretroviral Use On Survival In A Large Brazilian Seroprevalent Cohort 1996
Human T-Cell Lymphotropic Virus Type I Does Not Increase Hiv Viral Load In Vivo 1996
Diferenças Na Prevalência de Subtipos de Hiv-1 Entre Homens e Mulheres Participantes de Um Estudo de Coorte No Rio de Janeiro 1996
Impacto do Uso de Anti-Retroviral Na Sobrevida Em Uma Coorte de Pacientes Infectados Pelo Hiv. 1996
Infecção Por Hiv Em Mulheres: Análise Descritiva de Uma Coorte No Rio de Janeiro. 1996
Manifestações Neurológicas Associadas À Coinfecção Hiv/Htlv-1 1996
Prevalência de Marcadores de Doenças Sexualmente Transmissiveis Em Uma População Masculina de Alto Risco Para A Infecção Pelo Hiv 1996
Quantificação da Carga Viral de Hcv e de Hiv Em Pacientes Coinfectados Por Ambos Os Vírus 1996
Validação de Um Teste Rápido Para O Diagnóstico Sorológico Em Uma População Masculina de Alto Risco Para A Infecção Pelo Hiv. 1996
Detection of genetically diverse Human Immunodeficiency Virus Type I group M and O isolates by PCR 1996
Quantitative detection of Hepatitis C virus and Human Immunodeficiency Virus RNA in Brazilian Coinfected Patients. 1996
Coinfecção por HTLV-1 Não Aumenta a Carga Viral de HIV In Vivo. 1996
Incidência de Tuberculose (TB) Em Uma Coorte de Mulheres No Rio de Janeiro. 1996
Impacto do Uso de Anti-Retroviral na Sobrevida em Uma Coorte de Pacientes Infectados Pelo HIV 1996
Confirmation Of Homotypic Dual Infections With Hiv-1 And Phylogenetic Analyses Of The Contributing Subtypes 1995
Immune Diysfunction In Htlv-1 And Hiv Coinfection More Severe Than In Hiv Infection Alone. 1995
Myelopathy Among Brazilians Coinfected With Human T-Cell Lymphotropic Virus Type I And Hiv. 1995
Immune Dysfunction In Htlv-1 And Hiv Coinfection: Results Of A Pilot Study. 1995
Htlv I/Ii Infection In Brazilian Adult Patients With Neurologic Conditions. 1995
Infecção Pelo Virus Herpes Simples Resistente Ao Aciclovir. 1995
Genetic Variation In Protease Gene Of Hiv-1 In Rio de Janeiro 1995
In Vivo T-Cell Dysfunction In Coinfection With Human T-Cell Lymphotropic Virus Type I (Htlv-I) And Hiv. 1995
Characterization Of Hiv-I Dual Infection In Patients Of Rio de Janeiro. 1995
Frequency Of Subtypes Of Hiv-1 In Participants Of A Cohort Study In Rio de Janeiro As Suggested By Endonuclease Digestion Patterns Of The Protease Gene 1995
Differences In The Prevalence Of Hiv-1 Subtypes In Male And Famale Participants Of A Cohort Study In Rio de Janeiro 1995
Myelopathy Among Brazilians Coinfected With Human T-Cell Lymphotropic Virus Type I And Hiv 1995
Fluctuations in culutre of distinct HIV-1 strains from dually infected persons. 1995
Myelopathy Among Brazilians Coinfected With Human T-Cell Lymphotropic Virus Type I and HIV 1995
Identification Of Three Distinct Hiv-1 Subtypes In Brazil Based On The Protease Gene 1994
Reasons For Participating In Clinical Trials In Brazil. 1994
Full Sequence Of Gp120 Of An Hiv-1 Variant (Gwgr) Highly Prevalent In Brazil 1994
Hiv-1/Htlv-1 Coinfection Is Associated With A High Frequency Of Myelopathies. 1994
Heat Versus Acid Dissociation Of Immune Complexes for the detection of p24 antigenia 1994
Hiv-Infected Cells Can Kill Cd4+ Cells Upon Contact. 1994
Hiv-1, Htlv-1 And Tuberculosis Among Intravenous Drug Users In Rio de Janeiro, Brazil 1994
Myelopathy Among Brazilians Coinfected With Human T-Cell Lymphotropic Virus Type I And Hiv. 1994
HTLV-1-related neurologic manifestations among Brazilians subjects co-infected with HTLV-1 and HIV 1994
Full sequence of GP120 of an HIV-1 variant (GWGR) highly prevalent in Brazil 1994
HIV-1 and HTLV-1 infection: A case-control study. 1993
Clinical correlates of NK cell number and activity in HIV positive patients 1993
High prevalence of HIV-1 infection in a representative sample of childbearing women in Rio de Janeiro, Brazil. 1993
Prevalence of antibodies to Hepatitis C virus in populations at low and high risk for sexually transmitted diseases in Rio de Janeiro. 1993
Natural Killer cell function and number in HIV-1 positive patients: CD16/56+ with CD3- or CD3+ phenotype 1993
Prevalence of HTLV infection among heterosexual couples with HIV positive male index cases 1993
Correlates of p24 antigenemia in HIV-1 infected Brazilian individuals 1993
Correlates of reactivity to V3 loop peptides in HIV-1 infected patients in Rio de Janeiro, Brazil 1993
HIV-1 prevalence in 4536 childbearing women attending maternity wards in Rio de Janeiro: A model based in correspondence analysis 1993
Coinfection with Human T-cell Lymphotropic Virus Type I (HTLV-I) among adults with HIV infection in Brazil 1993
ENMG and SSEP Study in HTLV-1 patients. 1993
HIV-1 and HTLV-1 dual infection: Impact on CD4 counts and clinical stage 1993
Impact of co- infection with HTLV-1 and HIV on markers of HIV disease progression 1993
Antibiotic regimen as an independent risk factor for disseminated fungal infections in neutropenic patients 1993
A frequencia de antigenemia e sua correlacao com criterios evolutivos na infeccao pelo HIV no Brasil 1993
Aleitamento e transmissão vertical do HIV-1 1993
Correlates of p24 antigenemia in HIV-1 infected Brazilian individuals 1993
Prevalence of antibodies to Hepatitis C virus in populations at low and high risk for sexually transmitted diseases in Rio de Janeiro. 1993
Natural Killer cell function and number in HIV-1 positive patients: CD16/56+ with CD3- or CD3+ phenotype 1993
Clinical correlates of NK cell number and activity in HIV positive patients 1993
Eletroneuromiografia e potenciais evocados somato-sensitivos em pacientes com mielopatia associada ao HTLV-1 1993
Aleitamento Materno e transmissão vertical do HIV-1 1993
Fatores de risco para infecções fúngicas disseminadas em pacientes neutropênicos: Estudo caso-controle 1993
Survival of HIV- 1 infected Brazilian individuals: a model based on the WHO staging system 1992
Urinary Tract Infection Is More Common In AIDS Patients Than In Asymptomatic HIV-infected Individuals, Or In Non-HIV Infected Patients. 1992
PPD Reactivity and Risk of Development of Tuberculosis in HIV Infected Brazilian Patients. 1992
Prevalence of Retroviral Infections in Intravenous Drug Users in Rio de Janeiro, Brazil 1992
Measurement of false-positive rate in a screening program for HIV-1 among 1398 patients with tuberculosis in Rio de Janeiro, Brazil 1992
Antigenic and genomic diversity of the HIV-1 V oop: Analysis of geographical variation by serology , neutralization and sequencing. 1992
Private versus state medical care of AIDS patients in Rio de Janeiro, Brasil: Impact on survival 1992
Parenteral behaviour and vertical transmission of HIV-1 in Rio de Janeiro, Brasil. 1992
NK activity in HIV infected brazilian individuals with different degrees of immune disfunction 1992
Predictors of CD4 counts in HIV-infected Brazilian individuals: A model based on the WHO staging system 1992
A prospective evaluation of 6 AIDS case definitions in Rio de Janeiro, Brazil. 1992
Predicao de contagem de CD4 nos individuos infectados pelo HIV 1992
Prevalencia de anticorpos para o virus da Hepatite C em populacoes de baixo e alto risco para doencas de transmissao sexual 1992
Impacto da infeccao pelo HTLV-1 em pacientes infectados pelo HIV-1. 1992
Atendimento publico X Atendimento privado: Impacto na sobrevida de pacientes com AIDS 1992
Tuberculose infeccao e doenca entre comunicantes de paciente com tuberculose pulmonar e infeccao pelo HIV. Estudo prospectivo: Resultados preliminares. 1992
Mielopatia associada a infeccao por HTLV-1: Experiencia do HUCFF-UFRJ 1992
L'impact des manifestations neurologiques sur la survie des patients bresiliens atteints par le SIDA 1991
Vertical and horizontal transmission of HTLV-1 in 4 generations of a brazilian family 1991
Predictors of pulmonary tuberculosis in sputum-negative brazilian AIDS patients 1991
Predictors of fungemia in AIDS patients: A case-control study 1991
Soroprevalencia de HIV-1 nas pueperas do Rio de Janeiro: resultados prelminares. VI Congresso Brasileiro de Infectologia 1991
Alteracoes eletroneuromiograficas associadas a infeccao pelo HTLV-1 numa familia brasileira 1991
Estudo eletroneuromiografico em 10 pacientes com mielopatia associada ao HTLV-1. 1991
Lepra como causa de resultados falso-positivos em testes sorologicos para deteccao de anticorpos anti-HIV. 1991
Transmissao vertical e horizontal de HTLV-1 em 4 geracoes de uma familia 1991
Manifestations neurologiques associees a l'infection par l'HTLV-1 chez une famille bresilienne. 1991
A pre-evaluation of a new, WHO-sponsored staging system for HIV infection 1990
A higher than expected frequency of Histoplasmosis : Importance of routine obtention of blood cultures for fungi. 1990
Criteria for presumptive diagnosis of neurotoxoplasmosis : Are they adequate? 1990
Comparative study of neurological complications in 172 cases of HIV infection 1990
Dermatological findings in patients with advanced HIV-related disease in Brazil. 1990
Achados dermatologicos nos pacientes com doenca relacionada ao HIV em estagios Avancados no Brasil 1990
AIDS e Miopatia 1990
Criterios para o diagnostico de neurotoxoplasmose: Serao adequados ? Revisao de 80 casos. 1990
Complicacoes Neurologicas da SIDA/AIDS Experiencia do HUCFF-UFRJ 1990
Possible high frequency of bacteriuria among brazilian AIDS patients 1990
Natural history of HIV infection in Brazil and other parts of the world: A proposal for a comparative study 1990
Differences In Kelling Of Cd4 Cells Induced By Hiv Isoletes From Asymptomatic And Aids Patients. 1989
Associacao de Diabetes Insipidus central e AIDS 1989
Descriptive analysis of Trypanosoma cruzi surface antigen profile: variations induced by different methodologies 1987
Quantitation Of A 72,000 Mw Cell Surface Glycoprotein In T.Cruzi Zymodernes And Detection Of Anti-Gp 72 Antibodies In Patients Carrying Different Zymodernes 1985
GP25 antigen of Trypanosoma cruzi: Identification of a 60 Kd precursor with monoclonal antibodies 1985
Characterization of a cross-reactive antigen of T. cruzi defined with Sleeping Sickness sera 1985
Involvement of carbohydrate structures in the antigenicity of T. cruzi glycoproteins GP25 and GP 50/55. 1985
Identification of T. cruzi glycoprotein GP 50/55 as a cross-reactive antigen of Trypanosomatids 1985
Propects For Species And Strain Specific Diagnoses Of T.Cruzi Infection. 1984
Monoclonal Antibodies Which Define A 72 K Glycoprotein And Tissue Cross Reacting Antigens In T.Cruzi. 1983
Publicações:
Minha Rede: